Novo seeks a cardiovascular boost
An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.
Viking’s Voyage is not over yet
A hit on one goal helps, but future Nash data will be more decisive.
Medtronic plays catch-up in diabetes
The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.